Dr. Jinsong Liu is a professor with tenure in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center since 2009. He received his medical degree from Shanghai Medical University 1983 and completed his Ph.D. from Case Western Reserve University in 1991, and post-doctoral training at the University of Michigan in 1993, pathology residency and surgical pathology fellowship training at New York University in 1999. Dr. Liu is an internationally recognized for his expertise in diagnostic pathology and research achievements in ovarian cancer. Dr. Liu has co-authored 213 original publications and has been an editorial member of several reputable journals.
His research interest has focused on the mechanisms of epithelial tumorigenesis, inflammation, and cancer stem cells.
Dr Lagadec is an assistant professor at the French National Institute of Health and Medical Research. He received his PhD in 2007 on TrkA signaling in breast cancer and spent 5 years as a postdoc fellowship in Dr. Pajonk’s lab, a pioneer in CSC research field. Within his time at UCLA in the Radiation Oncology Department at David Geffen School of Medicine, he got trained on CSC and was the first to demonstrated the phenotype plasticity of CSC induced by radiation treatment. Since 2012, Dr. lagadec set up is own team in the INSERM U908 laboratory in Lille, France, where he studies the molecular mechanisms involved in the reprogramming process. He develops molecular tools and an animal model to track and characterise CSC and iCSC. His domain of interest enlarges recently to understand the potential role of reprogramming in tumor dormancy and metastasis development.
Dr Philippe Juin obtained his PhD degree in 1995 for his work on mitochondrial assembly. During his post-doc in the UK, he defined the mitochondrial apoptotic pathway as one major intrinsic tumor suppressor mechanism triggered by oncogene deregulation. As an Associate Researcher at INSERM, he led increasingly ambitious investigations of the regulation of the mitochondrial apoptotic pathway by Bcl-2 family members in human cancer cells and he created in 2012 an INSERM team that specifically focusses on the role of this pathway in stress adaptation and tumor escape. This team gained international recognition for its fundamental and translational research on the regulation of therapeutic response and tumor progression by BCL-2 family members (Nature Rev. Cancer 2013, Cell Rep. 2016, EMBO Rep. 2018 in press). This team contributed to establish that changes in mitochondrial apoptotic priming are at the core of breast cancer cells response to cytotoxic stress and treatments, being influenced by oncogene signaling, tumor suppressor pathways, therapy and tumor context. This team recently established a new function of BCL-2 members, that contributes contributing to the self renewal of breast cancer initiating cells, and defined the molecular events involved (Nature Comm., 2017).
Dr Philippe Juin and his team specifically focus on the role of this pathway in stress adaptation and tumor escape
Thierry Virolle is a Research Director (permanent position) at Institut National de la Santé et de la Recherche Médicale (INSERM), Head of the Team Cancer Stem Cell Plasticity and Functional intra-tumor Heterogeneity at the Institute of Biologie Valrose (iBV). He is Co-Founder of the French National Sud Cancer Stem Cell Network, SUNRiSE dedicated to the study of cancer stem cell.
Dr. Ralf Huss joined Definiens in 2013 and has more than 20 years of training and experience in histopathology and cancer research. Dr. Huss also co-founded the biotech company APCETH. He has published more than 100 papers, and has worked with the Nobel Laureates Rolf Zinkernagel and E. Donnell Thomas.
Dr. Jingfang Ju is the Professor in the Department of Pathology at Stony Brook Medicine/Stony Brook University. Dr. Ju received his BS degree from the Northeastern University and Ph.D. in molecular biology and biochemistry at the University of Southern California. He completed his post-doctoral research fellowship at Yale Cancer Center, Yale University. Previously Dr. Ju has served as the Senior Scientist and Team Leader of high throughput genomics at a biopharmaceutical company, CuraGen Corporation in Connecticut.
Dean Tang, PhD, was trained as a Pathologist and is currently Professor & Chair in Department of Pharmacology & Therapeutics at Roswell Park Cancer Institute. His Master of Science thesis research (1986-1989), conducted in Dr. Hong-shen Tian’s laboratory in Wuhan University School of Medicine, focused on establishing lung cancer metastasis models. To continue his research on metastasis, Dr. Tang joined Dr. Ken Honn’s lab at Wayne State University (WSU) in 1989 to study the role of integrin receptors in mediating tumor cell – extracellular matrix interactions, tumor cell invasion, and tumor cell extravasation. Dr. Tang obtained his PhD in Cancer Biology in 1994 and stayed at WSU for a few years to explore apoptosis-based anti-prostate cancer therapeutics. In 1998, he was awarded a Burroughs-Wellcome Hitchings-Elion post-doctoral Fellowship to study oligodendrocyte precursor cell (OPC) development in Dr. Martin Raff’s lab in Medical Research Council (MRC) Laboratory for Molecular & Cellular Biology (LMCB) of University College London (UCL, UK). Dr. Tang returned to America in June of 2000 to join the MD Anderson Cancer Center Department of Epigenetics and Molecular Carcinogenesis till May of 2016.
Dr. Xianming Mo is a professor of internal medicine and acts as Director of Laboratory of Stem Cell Biology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University. He obtained his medicine degree from North Sichuan Medical College. Then he was trained in pathology and accept Master of Medicine in West China University of Medical Science. After obtaining a PhD degree in Peking Union Medical College, He moved to Humboldt-Universität zu Berlin and then to Medical College of Georgia as postdoctoral fellows. Then, he became junior faculty in Medical College of Georgia and senior scientist in Max Delbruck Center for Molecular Medicine. In 2006, he returned back to West China Hospital.
Dr Philippe Juin and his team specifically focusses on the role of this pathway in stress adaptation and tumor escape
Dr Ilio Vitale received his Ph.D. in 2006 for the molecular characterization of mitotic catastrophe. During his 6-years post-doc in France he investigated the role of aneuploidy/tetraploidy in tumorigenesis uncovering surveillance mechanisms surveying cell ploidy (EMBOJ 2010, Science 2012). He is currently Group Leader and Adjunct Professor in Neuobiology at the University of Rome “Tor Vergata” working on the link between CSCs, chromosomal instability, and tumor immunity. His group recently identified a novel strategy for the depletion of CSCs based on CHK1 inhibition (Gut 2017, Mol Cell 2017). He is the Executive Editor of Molecular & Cellular Oncology, Subject Editor in the Reference Module in Life Sciences and served as Editor for several books. He received the Young Scientist Award from the European Environmental Mutagenesis Society (2013). He is author of >100 ISI papers (including Science, Nat Med, Nat Rev Mol Cell Biol., Nat Cell Biol). “h” index: 34.
Dr. Zhang graduated from Johns Hopkins University with PhD. He has worked at Harvard University Genome Center as Senior System Biologist for years before joining University of Hong Kong in 2013. Dr. Zhang lab has broad interest in genetic and epigenetic regulation in development and diseases. Currently, his lab is focusing on epigenetic regulation of tumorigenesis. His lab employs high through-put ‘omics’ assays and large scale computation to dissect the gene regulatory network and signaling pathways involved in oncogenesis.
Dr. Qien Wang is an Associatet Professor in the Department of Radiology and Comprehensive Cancer Center at the Ohio State University. Dr. Wang received his Bachelor Degree in Preventive Medicine in Shanxi Medical College in 1992, and obtained his PhD from Beijing Medical University in 1997 in China. Then, Dr. Wang worked as a Lecturer and Associate Professor at Peking University Medical Center for 4 years. During this time, his research was focused on understanding how gene and environmental exposure interact in carcinogenesis. In 2001, Dr. Wang joined Dr. Altaf Wani’s laboratory at the Ohio State University in the United States of America to study the mechanism of DNA repair as a Research Associate and Research Scientist. Since 2011, Dr. Wang has become a Tenure-track Assistant Professor at the Ohio State University, and was promoted to Associate Professor with Tenure in 2017.
Joo-Hyeon Lee was fascinated by stem cell research through Ph.D. studies under the supervision of Prof. Daesik Lim in KAIST, Korea. She then joined Prof. Carla Kim’s laboratory at Harvard Medical School where she became interested in the study of adult lung stem cells. She established her own research group at the Cambridge Stem Cell Institute in 2016 and focuses on understanding cellular behavior and regulatory networks of adult stem and niche cells. Joo-Hyeon is currently Faculty member at the Department of Physiology, Development, and Neuroscience, University of Cambridge and was recently awarded the Royal Society and Wellcome Trust Sir Henry Dale Fellowship and ERC starting grant.
Lee lab applies mouse genetics, ex vivo organoid co-cultures, live imaging, single-cell molecular analysis and mathematic modelling to define the identity and heterogeneity of diverse epithelial progenitor and mesenchymal populations, understand the key stem-mesenchymal interactions and the precise mechanisms that maintain tissue homeostasis and regeneration. Specifically, they are asking how the quiescent state is maintained and becomes activated, how cell fate is determined, and how niches develop and remodel in lung homeostasis, injury repair and early tumorigenesis.
Claire Acquaviva obtained her PhD at Montpellier University working on the proteolytic regulation of Fos transcription factors in Dr. Marc Piechaczyk’s laboratory at the Institute of Molecular Genetics of Montpellier (IGMM). She worked as a post-doc in Jonathon Pines’ laboratory at the Gurdon Institute in Cambridge (UK) on the regulation of the cell cycle by proteolysis. She returned to France in Marseille to work on the centrosome, primary cilia, cell cycle regulation and associated pathologies in Dr. Daniel Birnbaum’s laboratory at the CRCM.
Dr. Claire Acquaviva and Dr. Emilie Mamessier co-lead a group at the CRCM interested on Circulating Tumor Cells (CTCs) and their contribution to cancer metastases. Their main research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
Dr. Elaine Hurt received her PhD in Biochemistry, Molecular Biology and Biophysics from the University of Minnesota in 1999 where she studied estrogen receptor signaling cascades. Dr. Hurt did her post-doctoral studies at the National Institutes of Health in the laboratory of Dr. Louis Staudt elucidating the molecular mechanisms governing therapeutic responses in lymphoma and multiple myeloma patients. In 2010, Dr. Hurt joined MedImmune to lead their cancer stem cell group. Prior to joining MedImmune, Dr. Hurt was a Staff Scientist at the National Cancer Institute, where she focused primarily on identifying and targeting prostate cancer stem cells. In 2014, Dr. Hurt became Adjunct Associate Professor in the Department of Biochemistry and Molecular Biology at the University of Maryland. She is the co-inventor on several patents, has been an invited speaker at numerous conferences, and has published over 50 scientific articles.
Dr. Hurt’s research is aimed at developing novel therapeutics to treat cancer. In particular, she is focused on understanding and developing targets against cancer stem cells. In recent years, there is a focus on understanding how cancer stem cells shape and interact with the immune cells of tumor microenvironment.
A/Prof Yong Li obtained his PhD degree at University of New South Wales (UNSW) Sudney, Australia in 2000. He became Cancer Research Group leader in 2006, and is an established cancer researcher, with expertise in cancer biomarker discovery, radiation biology, target cancer therapy and cancer metastasis. He was awarded an NHMRC Career Development Fellowship (Level 2) in 2010-2014; and an NHMRC Achievement Award (ranked No.1 in the industry fellow) in 2011. He was promoted to an Associate Professor in the Faculty of Medicine, UNSW since 2011, and a Principal Scientific Officer by the South Eastern Sydney Local Health District (SESLHD) since 2012. A/Prof Li has more than 100 career publications in cancer research area since 1999.
Guo-fu Hu, PhD, is currently a Professor of Medicine, Tufts University School of Medicine, and an Investigator at Tufts Medical Center. He received his PhD from Shanghai Institute of Biochemistry, Chinese Academy of Sciences, and did his postdoctoral training in Beret L. Vallee lab located at the Center for Biochemical and Biophysical Sciences and Medicine, Harvard Medical School. He established his research program first in the Department of Radiology, Brigham and Women’s Hospital, and then in the Department of Pathology, Harvard Medical School, where he raised to the rank of Associate Professor of Pathology. He moved to Tufts Medical Center in 2010.
Emmanuelle Charafe-Jauffret is a doctor of medicine and a specialist in breast cancer, and is known for her expertise in cancer stem cells.
She led a group on the characterization of cancer stem cells in the gland breast.
Hervé Chneiweiss, first trained as a neurologist (movement disorders, Parkinson), HC was involved in the neurogenetics of human diseases such as cerebellar ataxias. For the last 15 years his scientific work was dedicated to the biology of astrocytes and their roles in brain tumor progression. He created in 2006 the Inserm laboratory U752, which gathered scientists and clinicians devoted to the study of brain tumors. HC is since 2014 director of the laboratory Neuroscience Paris Seine.
Emilie Mamessier performed her Ph.D. at Aix-Marseille University, followed by a postdoc at the Institute for Child health Research in Perth (Pr. P Holt, Australia) working on deregulated immune responses in asthma. Ten years ago, she switched to study cancer development, notably with the characterization of early stages of cancer, both at the tumor cell level and in relation to tumor microenvironment composition (CRCM and Center of Immunology Marseille Luminy CIML, Marseille).
Emilie Mamessier research interest is focused on breast and colon cancers and aim at better defining CTCs at high risk of seeding metastases. For this, they are combining innovative technologies (single cells isolation, microfluidic …) with complex organoids generation, either as a source (tumoroid) or a receptacle (multicellular organoid) for CTCs.
After graduating from the Royal College of Surgeons in Ireland in 2004 with a PhD in Oncology, Stephen Maher spent 3 years as a visiting fellow at the National Cancer Institute in the US. In 2007 he returned to Ireland and Trinity College Dublin, St. James’s Hospital as a research fellow. In 2010 he established his own research group having secured an Irish Cancer Society Fellowship and a number of Health Research Board grants, predominantly in the area of radiation resistance in the treatment of gastrointestinal malignancy. In 2012 Stephen moved to the University of Hull and Hull York Medical School as a senior lecturer, where he led the Cancer Biology and Therapeutics lab. In 2016 Stephen returned to Trinity College Dublin as the James Ussher Assistant Professor in Translational Oncology, where he has set up new cancer radiobiology and hypoxia research cores.
Dr Philippe Juin and his team specifically focusses on the role of this pathway in stress adaptation and tumor escape
Laurie J. Gay earned her Ph.D. at The Scripps Research Institute in La Jolla, California as a NIH Clinical and Translational Science Award Scholar. During this time, her research focused on the creation of metastasis models for understanding systemic and host influences on distant tumor development, especially brain metastasis. In 2013, she joined the laboratory of Dr. Ilaria Malanchi in her current position of Cancer Research UK Postdoctoral Fellow at the London Research Institute (now part of the Francis Crick Institute) in London.